These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 11716799

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
    Pu Q, Larouche I, Schiffrin EL.
    Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
    [Abstract] [Full Text] [Related]

  • 3. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
    Mifsud SA, Burrell LM, Kubota E, Jaworski K, Cooper ME, Wilkinson-Berka JL.
    Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
    [Abstract] [Full Text] [Related]

  • 4. Role of Angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling.
    Korshunov VA, Massett MP, Carey RM, Berk BC.
    J Vasc Res; 2004 Jan; 41(2):148-56. PubMed ID: 15004434
    [Abstract] [Full Text] [Related]

  • 5. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
    Bäcklund T, Palojoki E, Saraste A, Grönholm T, Eriksson A, Lakkisto P, Vuolteenaho O, Nieminen MS, Voipio-Pulkki LM, Laine M, Tikkanen I.
    Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats.
    Pu Q, Schiffrin EL.
    Am J Hypertens; 2001 Oct; 14(10):1067-72. PubMed ID: 11710787
    [Abstract] [Full Text] [Related]

  • 8. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat.
    Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH, Diz DI.
    Kidney Int; 2002 Oct; 62(4):1349-57. PubMed ID: 12234305
    [Abstract] [Full Text] [Related]

  • 9. Omapatrilat induces profound renal vasodilation but does not affect coronary hemodynamics.
    Varagic J, Susic D, Slama M, Frohlich ED.
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):167-74. PubMed ID: 12808490
    [Abstract] [Full Text] [Related]

  • 10. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
    Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE.
    Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
    [Abstract] [Full Text] [Related]

  • 11. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
    Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI.
    Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences.
    Graham D, Hamilton C, Beattie E, Spiers A, Dominiczak AF.
    J Hypertens; 2004 Feb; 22(2):329-37. PubMed ID: 15076191
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
    Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR.
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
    [Abstract] [Full Text] [Related]

  • 16. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E, Jovanoska E, Zafirov D, Jakovski K, Maleska V, Slaninka-Miceska M.
    Bratisl Lek Listy; 2005 Mar; 106(12):407-11. PubMed ID: 16642666
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor.
    Azizi M, Massien C, Michaud A, Corvol P.
    Hypertension; 2000 Jun; 35(6):1226-31. PubMed ID: 10856268
    [Abstract] [Full Text] [Related]

  • 18. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T, Cheng ZJ, Palojoki E, Eriksson A, Bäcklund T, Vuolteenaho O, Finckenberg P, Laine M, Mervaala E, Tikkanen I.
    Eur J Pharmacol; 2005 Sep 20; 519(3):267-76. PubMed ID: 16137672
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
    Lapointe N, Blais C, Adam A, Parker T, Sirois MG, Gosselin H, Clément R, Rouleau JL.
    J Am Coll Cardiol; 2002 May 15; 39(10):1692-8. PubMed ID: 12020499
    [Abstract] [Full Text] [Related]

  • 20. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
    Loch D, Hoey A, Brown L.
    Clin Exp Hypertens; 2006 Jul 15; 28(5):475-88. PubMed ID: 16820344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.